Statin use may improve overall survival and reduce risk of recurrence in resected NSCLC patients

Published on October 22, 2012 at 1:25 AM · No Comments

Patients who have undergone resection for non-small cell lung cancer (NSCLC) may improve their overall survival and reduce the risk of recurrence by taking statins. Researchers from Northwestern University Feinberg School of Medicine, Chicago, and Penn State Hershey Cancer Institute followed 803 patients who underwent resection for NSCLC, of which 315 were using statins.

Results showed that statin use was associated with a significantly lower local recurrence rate and significantly higher overall survival compared with non-statin users. Researchers conclude that prospective studies are needed to assess the role of statin therapy as an adjunct to current multimodality regimens. This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 - 25, in Atlanta, Georgia.

Source: American College of Chest Physicians

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post